Literature DB >> 25384767

Treatment principles for Candida and Cryptococcus.

Laura C Whitney1, Tihana Bicanic2.   

Abstract

The yeasts Candida and Cryptococcus spp. are important human opportunistic pathogens. Candida spp. rely on skin or mucosal breach to cause bloodstream infection, whereas Cryptococcus spp. exploit depressed cell-mediated immunity characteristic of advanced HIV infection. The treatment for both organisms relies on the administration of rapidly fungicidal agents. In candidaemia, source control is important, with removal of prosthetic material and drainage of collections, as well as hunting for and tailoring therapy to disseminated sites of infection, particularly the eyes and heart. For cryptococcal meningitis, restoration of immune function through antiretroviral therapy (ART) is key, together with careful management of the complications of raised intracranial pressure and relapsed infection, both pre- and post-ART.
Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25384767      PMCID: PMC4448702          DOI: 10.1101/cshperspect.a024158

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  92 in total

1.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Authors:  Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

2.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

Review 3.  HIV-associated cryptococcal meningitis.

Authors:  Joseph N Jarvis; Thomas S Harrison
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

4.  [Autopsy results of deep mycoses in hematologic neoplasms (1053 patients].

Authors:  K Donhuijsen; B Pfaffenbach; S Samandari; L D Leder
Journal:  Mycoses       Date:  1991       Impact factor: 4.377

5.  Candida glabrata endophthalmitis treated successfully with caspofungin.

Authors:  Juan C Sarria; Jay C Bradley; Ranya Habash; Kelly T Mitchell; Robert C Kimbrough; Ana M Vidal
Journal:  Clin Infect Dis       Date:  2005-02-01       Impact factor: 9.079

6.  European expert opinion on the management of invasive candidiasis in adults.

Authors:  B J Kullberg; P E Verweij; M Akova; M C Arendrup; J Bille; T Calandra; M Cuenca-Estrella; R Herbrecht; F Jacobs; M Kalin; C C Kibbler; O Lortholary; P Martino; J F Meis; P Muñoz; F C Odds; B E De Pauw; J H Rex; E Roilides; T R Rogers; M Ruhnke; A J Ullmann; Ö Uzun; K Vandewoude; J-L Vincent; J P Donnelly
Journal:  Clin Microbiol Infect       Date:  2011-09       Impact factor: 8.067

7.  Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.

Authors:  G M Gauthier; T M Nork; R Prince; D Andes
Journal:  Clin Infect Dis       Date:  2005-06-28       Impact factor: 9.079

8.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 9.  Cryptococcosis in solid organ transplant recipients: current state of the science.

Authors:  Nina Singh; Francoise Dromer; John R Perfect; Olivier Lortholary
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

10.  High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial.

Authors:  Tihana Bicanic; Robin Wood; Graeme Meintjes; Kevin Rebe; Annemarie Brouwer; Angela Loyse; Linda-Gail Bekker; Shabbar Jaffar; Thomas Harrison
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

View more
  5 in total

Review 1.  Treatment principles for the management of mold infections.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

Review 2.  Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis.

Authors:  Kyung J Kwon-Chung; James A Fraser; Tamara L Doering; Zhou Wang; Guilhem Janbon; Alexander Idnurm; Yong-Sun Bahn
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-01       Impact factor: 6.915

Review 3.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

4.  Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy.

Authors:  Suresh Ambati; Emma C Ellis; Jianfeng Lin; Xiaorong Lin; Zachary A Lewis; Richard B Meagher
Journal:  mSphere       Date:  2019-10-30       Impact factor: 4.389

5.  Potential Predictors and Survival Analysis of the Relapse of HIV-Associated Cryptococcal Meningitis: A Retrospective Study.

Authors:  Yao Li; Yanqiu Lu; Jingmin Nie; Min Liu; Jing Yuan; Yan Li; Huan Li; Yaokai Chen
Journal:  Front Med (Lausanne)       Date:  2021-05-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.